Core Insights - The strategic partnership between Meinian Health and Aihui Long aims to integrate advanced in vitro diagnostic technology with a vast health examination network and AI health management platform to enhance disease screening efficiency and preventive medicine levels [1][3] Group 1: Strategic Collaboration - The signing ceremony for the strategic cooperation took place in Shanghai, attended by key figures from both companies, indicating a significant milestone for Meinian Health in deepening health service capabilities [3] - The collaboration is expected to enrich Meinian's health examination products with Aihui Long's cutting-edge diagnostic projects in areas such as autoimmune diseases, cardiovascular issues, diabetes, and central nervous system diseases [3][4] Group 2: Health Management Ecosystem - The partnership will focus on four core areas to create a comprehensive health management service system that spans prevention, detection, treatment, and management, aligning with national health management guidelines [4] - Aihui Long will assist Meinian Health in developing tailored autoimmune disease screening packages to identify high-risk individuals early and provide timely interventions [4] Group 3: Disease-Specific Management - The collaboration will establish a comprehensive management system for cardiovascular diseases, integrating prevention, diagnosis, treatment, and management, supported by Aihui Long's precise cardiovascular disease marker detection [5][6] - For diabetes, the partnership will cover the entire risk management chain, from early screening to functional assessment, providing a full-cycle service to mitigate chronic disease impacts [7] Group 4: Neurological Disease Prevention - Aihui Long's advancements in early warning systems for central nervous system diseases, including Alzheimer's, will be integrated with Meinian Health's services to enhance early detection and intervention capabilities [8] - The collaboration aims to shift the paradigm of health management for neurological diseases from passive treatment to proactive health strategies, contributing to the "Healthy China" initiative [8]

证券代码：002044 证券简称：美年健康 公告编号：2025-091 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2024 年 12 月 13 日召开第九届董事会第五次（临时）会议及 2024 年 12 月 30 日召开 2024 年第六次临时股东大会，审议通过《关于公司及下属子公司申请融资额度并提供 担保的议案》，同意公司及部分下属子公司 2025 年度为公司及合并报表范围内的 子公司提供担保额度累计不超过人民币 49 亿元。具体内容详见公司于 2024 年 12 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司及下属子公司申请 融资额度并提供担保的公告》（公告编号：2024-111）。 二、进展情况 三、被担保方基本情况 1.美年大健康产业（集团）有限公司 成立日期：2004 年 6 月 8 日 法定代表人：俞熔 注册地址：上海市闵行区东川路 555 号乙 B203 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-090 美年大健康产业控股股份有限公司 关于召开 2026 年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）2026 年第一次临时股东会现场会议的召开地点为上海市静安区灵石路 697 号健康 智谷 9 号楼三楼公司会议室，敬请投资者特别留意。 根据公司于 2025 年 12 月 16 日召开的第九届董事会第十六次（临时）会 议，定于 2026 年 1 月 6 日召开公司 2026 年第一次临时股东会，本次股东会将 采用股东现场记名投票与网络投票表决相结合的方式召开，《关于召开 2026 年第一次临时股东会的通知》（公告编号：2025-087）已于 2025 年 12 月 17 日 披露在《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资 讯网（www.cninfo.com.cn）。现就本次股东会的有关事宜发布提示性公告如下： 一、召开会议的基本情况 1.股东会届次：2026 ...

Core Insights - The strategic partnership between Meinian Health and Aihuilong aims to integrate advanced in vitro diagnostic technology with a vast health examination network and AI health management platform to enhance disease screening efficiency and preventive medicine levels [1][2] Group 1: Partnership Objectives - The collaboration focuses on building a comprehensive health management service system that spans prevention, diagnosis, treatment, and management, aligning with national health management guidelines [2][3] - Meinian Health's Chairman emphasized that this partnership is a significant milestone in deepening health service capabilities and enhancing professional barriers [2] Group 2: Specific Areas of Focus - Aihuilong will assist Meinian Health in customizing autoimmune disease screening packages tailored to different examination populations, enabling early identification and risk warning for high-risk individuals [3] - The partnership will establish a comprehensive management system for high-risk cardiovascular patients, integrating prevention, diagnosis, treatment, and management into a closed-loop healthcare pathway [3] Group 3: Future Vision - The collaboration aims to create a continuously evolving and collaboratively innovative health management ecosystem that provides proactive health management services across the entire life cycle [4] - This initiative supports the national chronic disease prevention strategy and contributes to the broader "Healthy China" vision through industry innovation [4]

成交情况来看，上述26只机构预测高增长的智能体概念股中，截至12月29日收盘，12月以来日均成交额 环比增长的有9只，其中6股环比增幅超20%，分别是美格智能、美年健康、莲花控股、传音控股、拓邦 股份、道通科技。 从未来增长潜力来看，根据5家以上机构一致预测，2026年、2027年净利润增速均有望超过20%的AI智 能体概念股有26只。机构预测净利润增速均值在100%以上的概念股有5只，分别是昆仑万维、用友网 络、国投智能、启明星辰、安恒信息。 据数据宝统计，今年以来共有17只AI智能体概念股获机构调研10次以上。包括中控技术、广电运通、 顺网科技、宇信科技、邦彦技术等。 ...

Core Insights - The article reports on a strategic cooperation agreement signed between Aihuilong and Meinian Health on December 29, aimed at integrating advanced in vitro diagnostic technology with a vast health examination network and AI health management platform [1] Group 1: Strategic Partnership - Aihuilong and Meinian Health are collaborating to enhance disease screening efficiency and preventive medicine levels [1] - The partnership focuses on exploring data-driven disease risk model construction and optimizing personalized health management solutions [1] - The goal is to create a closed-loop health management pathway through the integration of their respective technologies and platforms [1]

（文章来源：证券日报） 证券日报网讯 12月29日，美年健康在互动平台回答投资者提问时表示，公司股东人数请详见公司的定 期报告。 ...

Market Overview - The A-share market saw a majority of indices decline, with the Shanghai Composite Index closing at 3965.28 points, up 0.04%, while the Shenzhen Component Index fell by 0.49% to 13537.1 points, and the ChiNext Index decreased by 0.66% to 3222.61 points. The total trading volume for both markets was 21,393.38 billion yuan, a decrease of 208.54 billion yuan from the previous trading day [1]. Capital Flow - The net outflow of main funds from the Shanghai and Shenzhen markets exceeded 48 billion yuan, with a net outflow of 221.26 billion yuan at the opening and 77.92 billion yuan at the close, totaling 482.76 billion yuan for the day [2]. - The CSI 300 index experienced a net outflow of 142.73 billion yuan, while the ChiNext saw a net outflow of 183.32 billion yuan [3]. Sector Performance - The banking sector recorded a net inflow of 29.83 billion yuan, with a growth of 0.53%, led by Agricultural Bank of China. The oil and petrochemical sector also saw a net inflow of 9.63 billion yuan, increasing by 0.74% [5]. - Conversely, the power equipment sector faced a significant net outflow of 156.07 billion yuan, decreasing by 0.62%, followed by non-ferrous metals with a net outflow of 97.25 billion yuan, down 0.82% [5]. Institutional Activity - The top stocks with institutional net purchases included Tianji Co., with a net buy of 168.29 million yuan, and Yingfeite, which saw a 20% increase in its stock price [8]. - Notable stocks with significant institutional net selling included Haige Communication, with a net sell of 71.20 million yuan, and Jin Feng Technology, which experienced a 10.01% increase but still faced substantial selling pressure [8]. Analyst Recommendations - Analysts have given a "Buy" rating to stocks such as Jingpin Special Equipment with a target price of 114 yuan, representing a potential upside of 43.02% from its latest closing price of 79.71 yuan. Other recommended stocks include Bailong Chuangyuan and Huanxu Electronics, with target prices indicating significant upside potential [10].

Group 1 - The "2025 Responsibility Shine Qilu" annual health event highlighted the importance of health management and recognized outstanding contributions in the healthcare sector [1] - The event announced the "Top Ten Health News in Shandong" and awarded titles such as "Responsible Hospital," "Responsible Department," and "Responsible Medical Practitioner" [1] - The launch of the "Yidian Ask Doctor" digital doctor service and the initiation of the "Yidian Ask Doctor" national health protection series for 2026 were also key highlights of the event [1] Group 2 - Meinian Health Industry (Shandong) Co., Ltd. was established in 2015 and is part of Meinian Health Industry Holdings Co., Ltd., a leading private healthcare enterprise in China [3] - The company operates under three health examination brands: "Mienian Health," "Ciming," and "Ciming Aoya," with over 40 examination centers across 16 cities in Shandong [3] - Meinian Health serves nearly 3 million health examination clients annually, focusing on health consultation, assessment, and management, supported by a vast network and health data [3]

Group 1 - The National Venture Capital Guidance Fund has officially launched, focusing on early-stage investments in sectors such as integrated circuits, artificial intelligence, aerospace, and low-altitude economy [1][3] - The fund aims to mobilize nearly 1 trillion yuan in local and social capital through its establishment [3] - Three regional sub-funds have been established in Beijing, Shanghai, and Shenzhen, with total scales of 296.46 billion yuan, 471 billion yuan, and 450.5 billion yuan respectively [3] Group 2 - The fund features a three-tier structure: national mother fund, regional mother funds, and sub-funds, with a 20-year duration to promote "patient capital" [4] - Sub-funds are required to invest 70% of their capital in seed and early-stage projects, without regional reinvestment obligations [4] - The private equity and venture capital market is expected to see a significant increase, with a 37.42% year-on-year growth in new registered funds by Q3 2025 [4] Group 3 - State-owned capital dominates the LP market with an investment of 123.12 billion yuan, accounting for 46.8% of total contributions [5] - Corporate investors contribute 44.15 billion yuan, representing 16.8% of the total, primarily from industrial groups and listed companies [5] - Nearly 300 listed companies have engaged in or are planning to establish investment funds this year [5] Group 4 - Companies like Meinian Health and Binhua Co. are actively participating in venture capital by establishing or investing in funds focused on AI, automation, and strategic emerging industries [6][7] - The investment strategies of these companies aim to enhance their competitive edge and align with their long-term strategic goals [6][7] - The establishment of investment funds by listed companies is seen as a way to expand business opportunities and leverage professional investment capabilities [9]